» Articles » PMID: 36506416

What Evidence is There for Implicating the Brain Orexin System in Neuropsychiatric Symptoms in Dementia?

Overview
Specialty Psychiatry
Date 2022 Dec 12
PMID 36506416
Authors
Affiliations
Soon will be listed here.
Abstract

Neuropsychiatric symptoms (NPS) affect people with dementia (PwD) almost universally across all stages of the disease, and regardless of its exact etiology. NPS lead to disability and reduced quality of life of PwD and their caregivers. NPS include hyperactivity (agitation and irritability), affective problems (anxiety and depression), psychosis (delusions and hallucinations), apathy, and sleep disturbances. Preclinical studies have shown that the orexin neuropeptide system modulates arousal and a wide range of behaviors a network of axons projecting from the hypothalamus throughout almost the entire brain to multiple, even distant, regions. Orexin neurons integrate different types of incoming information (e.g., metabolic, circadian, sensory, emotional) and convert them into the required behavioral output coupled to the necessary arousal status. Here we present an overview of the behavioral domains influenced by the orexin system that may be relevant for the expression of some critical NPS in PwD. We also hypothesize on the potential effects of pharmacological interference with the orexin system in the context of NPS in PwD.

Citing Articles

Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms.

Kwon K, Kim H, Han S, Shin C Int J Mol Sci. 2024; 25(21).

PMID: 39518892 PMC: 11547068. DOI: 10.3390/ijms252111338.

References
1.
Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase M . Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study. Int J Neuropsychopharmacol. 2021; 24(12):965-976. PMC: 8653874. DOI: 10.1093/ijnp/pyab050. View

2.
Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E . Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol. 2011; 26(8):1058-70. DOI: 10.1177/0269881111408954. View

3.
Lungwitz E, Molosh A, Johnson P, Harvey B, Dirks R, Dietrich A . Orexin-A induces anxiety-like behavior through interactions with glutamatergic receptors in the bed nucleus of the stria terminalis of rats. Physiol Behav. 2012; 107(5):726-32. PMC: 3482273. DOI: 10.1016/j.physbeh.2012.05.019. View

4.
Falkner A, Grosenick L, Davidson T, Deisseroth K, Lin D . Hypothalamic control of male aggression-seeking behavior. Nat Neurosci. 2016; 19(4):596-604. PMC: 4853470. DOI: 10.1038/nn.4264. View

5.
Cosin C, Sibon I, Poli M, Allard M, Debruxelles S, Renou P . Circadian sleep/wake rhythm abnormalities as a risk factor of a poststroke apathy. Int J Stroke. 2014; 10(5):710-5. DOI: 10.1111/ijs.12433. View